By Yuri Mikulka, Thomas F. Zuber, and Benjamin C. Deming of Zuber & Taillieu LLP
In a long-awaited opinion, the U.S. Supreme Court affirmed the Federal Circuit Court’s ultimate holding in In Re Bilski, but held that the Federal Circuit’s machine-or-transformation test is not the sole test for patentability of a claimed process. Bilski v. Kappos, ___ U.S. ___, 2010 WL 2555192, No. 08-964 (June… More...
The Strategic Manufacturing & Job Repatriation Act seeks to develop a national manufacturing strategy to create American jobs. More...
U.S. House of Representatives Judiciary Committee Chairman John Conyers, Jr. (D-Mich.) and Committee Ranking Member Lamar Smith (R-Texas) have introduced the Patent and Trademark Office Funding Stabilization Act. More...
U.S. Secretary of Commerce Gary Locke submitted a letter to members of the Senate Judiciary Committee expressing the administration’s view that the draft Manager’s Amendment to existing Senate patent reform legislation will make the reforms more effective upon implementation. Reforming the patent system will accelerate economic growth and job creation, and expand America’s ability to innovate. More...
Leaders of the Senate Judiciary Committee have announced details of an agreement on long-pending legislation to make needed reforms to the nation’s patent system. More...
Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office (“USPTO”) David Kappos has announced President Barack Obama’s $2.322 billion fiscal year 2011 (FY 2011) budget request for the USPTO. More...
The U.S. Senate Judiciary Committee has voted to pass a compromise version of Senator Herb Kohl’s bill banning pay-for-delay settlements that keep generic drugs off the market. More...
Both Houses of Congress have passed a bill authorizing the Director of the U.S. Patent and Trademark Office (“USPTO”) to establish a surcharge on patent fees to repay any borrowed trademark fees. More...
Sen. Bill Nelson, D-Fl., has filed a proposed legislation to amend Hatch-Waxman Act's definition of “first applicant” for abbreviated new drug application (“ANDA”) filers to give generic-drug makers challenging brand-name patents an opportunity at receiving 180-day market exclusivity. More...
Rep. Bobby L. Rush, D-Il., has re-introduced on the congressional floor a bill intended to eliminate perceived anticompetitive settlements of patent infringement litigation between generic and brand-name pharmaceutical manufacturers. More...
U.S. Senator Jon Kyl (R-Az) has filed his own version of Patent Reform Act of 2009 (S. 610). More...
